ALLUVI: A IN-DEPTH EXAMINATION INTO RETATRUTIDE'S PROSPECTS

Alluvi, known as BI 4744, represents a promising advance in weight control therapy. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling effectiveness in clinical trials, potentially surpassing available GLP-1 target agonists.